TransMedics Group (TMDX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $108.8 million, up 64% year-over-year, driven by increased OCS utilization, logistics services, and higher sales of OCS Liver, Heart, and Lung disposable sets.

• Net income was $4.2 million ($0.12 per diluted share) in Q3 2024, reversing a net loss of $25.4 million in Q3 2023.

• Gross margin declined to 56% from 61% in Q3 2023, mainly due to a higher mix of service revenue and investments in logistics and NOP network.

• Ended Q3 2024 with $330.1 million in cash, down from $362.8 million at the end of Q2, reflecting $7 million in operating cash generation and $42 million spent on aircraft purchases.

• All three OCS products (Heart, Lung, Liver) have FDA Pre-Market Approval for both DBD and DCD organs.

Financial highlights

• Q3 2024 total revenue was $108.8 million, up 64% year-over-year, but down 5% sequentially from Q2; nine-month revenue was $319.9 million, up 99% year-over-year.

• U.S. revenue grew 76% year-over-year to $104.9 million, with a 3% sequential decline; OUS revenue was $2.6 million, down 40% year-over-year.

• Gross profit for Q3 2024 was $60.8 million (56% margin), up from $40.7 million (61% margin) in Q3 2023.

• Product margin reached 80%, up from 77% in Q3 2023; service margin was 19%, impacted by non-recurring costs and higher third-party logistics use.

• Operating expenses for Q3 2024 were $56.9 million, down from $69.0 million in Q3 2023, which included $27.2 million in non-recurring R&D.

Outlook and guidance

• Full-year 2024 revenue guidance maintained at $425–$445 million, representing 76–84% growth over 2023.

• Early Q4 trends indicate normalization of transplant volumes, supporting confidence in guidance.

• Margins expected to remain variable in the near term due to ongoing investments, but anticipated to improve as scale and operational efficiencies increase.

• Long-term gross margin target remains in the mid-60% range, dependent on increased use of owned aircraft and service efficiency.

• Existing cash is expected to fund operations, capex, and debt service for at least 12 months.